BioCardia, Inc. 8-K

What Happened

• BioCardia, Inc. (BCDA) filed a Form 8-K on May 21, 2026 disclosing a press release about an oral presentation at EuroPCR in Paris. Dr. Amish Raval, M.D. (Univ. of Wisconsin) presented preliminary results from the open‑label cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia (CardiAMP CMI) trial.
• The data presented showed the minimally invasive, autologous CardiAMP procedure was well tolerated with no treatment‑emergent major adverse cardiac events reported in the cohort, and patients demonstrated sustained clinical improvements through two years of follow‑up.

Key Details

• Presentation: EuroPCR (Paris); press release dated May 21, 2026 (filed as Exhibit 99.1 on the 8-K).
• Safety: No treatment‑emergent major adverse cardiac events reported in the preliminary open‑label cohort.
• Efficacy signals: Average increase in exercise tolerance of 179 seconds sustained through two years; angina episode frequency reduced by an average of 82% by six months.
• Patient background: All patients were on guideline‑directed medical therapy and had received available percutaneous and/or surgical options as appropriate prior to treatment.

Why It Matters

• For investors, these results are a material clinical update: demonstrated safety and durable symptom improvement (up to two years) can de‑risk aspects of BioCardia’s CardiAMP clinical program and support ongoing development or regulatory discussions.
• The filing is a Regulation FD disclosure of a conference presentation and does not include financial results, guidance, or changes in management. Investors should treat these as preliminary, open‑label data and watch for full trial data, peer‑reviewed publications, or regulatory filings for confirmatory evidence.